PLA is pleased to announce Next Generation Sequencing (NGS) for solid tumor biomarker testing is now being performed on site at our laboratory in Tulsa, Oklahoma.

PLA is pleased to announce that Next Generation Sequencing (NGS) for solid tumor biomarker testing is now being performed on site at our laboratory in Tulsa, Oklahoma. This will significantly decrease the time waiting for results to help guide treatment decisions for oncology patients in comparison to current send-out testing. We are utilizing the ThermoFisher Genexus™ instrumentation with the Oncomine Precision Assay™ (OPA) and bioinformatics that is updated monthly to include reporting of the latest developments in treatment options and clinical trials. The OPA analyzes 78 variants including mutations, copy number variants and fusion variants across 50 key genes including cancer drivers, tumor suppressor genes and resistance mutations. Novel fusion detection chemistry allows detection of as few as 5 gene copies and requires the least amount of nucleic acid input compared to other NGS platforms, thus “quantity not sufficient” results will be significantly reduced. Tumor types that may benefit from NGS include, but are not limited to, NSCLC, Colorectal Cancer, Melanoma, Breast Cancer, Gastric Cancer, Cervical Cancer and Unspecified Solid Tumors.

Genes included in our NGS panel:

Sample type: Formalin Fixed Paraffin Embedded Tissue (FFPE) with at least 5% tumor

For further information or questions, contact Dr. Cindi Starkey 918-770-4426 or Patti Loykasek 918-770-4519. Orders may be faxed to Pathology Laboratory Associates at 918-416-0506. Insurance pre-authorization may be required prior to testing.